LadRx Corporation (formerly known as CytRx Corporation) is a biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer. CytRx's initial focus is on seeking regulatory approval for and commercialization of its lead drug candidate, aldoxorubicin, an improved version of the widely used chemotherapeutic agent doxorubicin.